Objective – The primary aim of this study was to assess, in Still’s disease, whether the employment of canakinumab at a strictly on-label dose may increase the likelihood of treatment discontinuation due to study-defined long-term remission (LTR), compared with patients receiving lower doses. Methods – Patients were drawn from the international Autoinflammatory Disease Alliance (AIDA) Network registry dedicated to Still’s disease and stratified based on the starting canakinumab dose: the on-label group received either 300mg every 4 weeks or 150mg every 4 weeks (corresponding to 4mg/kg), while the underdosed group received 150mg every 4 weeks (corresponding to a dose not exceeding 3.5mg/kg). Bayesian regression models were implemented to estimate the probability of achieving long-term remission with subsequent canakinumab withdrawal in the two groups, as well as the mean differences in probabilities and posterior probabilities indicating whether the on-label group was superior in achieving the endpoint. Results – In total, 131 patients (16.7%) were enrolled, 81 (61.8%) receiving the on-label posology and 50 (38.2%) the underdosed posology. The estimated marginal posterior probability of canakinumab discontinuation due to LTR was 19% (CrI 7.5%–34.6%) in the on-label group and 3.9% (CrI 0.7%–15.2%) in the underdosed group, yielding a mean difference of 15.1% (CrI 1.4%–31.4%) and a posterior probability of 98.4%. This difference remained credible, with posterior probabilities ranging from 97.9% to 99.6%, irrespective of disease course or age at disease onset. Conclusion – On-label canakinumab dosing appears to increase the likelihood of study-defined LTR with subsequent treatment discontinuation, compared with underdosed treatment strategies.
Association between canakinumab dose and long-term remission in Still’s disease: insights from the AIDA network registry / Vitale, A., Caggiano, V., Sbalchiero, J., Lopalco, G., Tufan, A., Ragab, G., Sfikakis, P.P., Dagna, L., Batu, E.D., Ozen, S., Conti, F., Maiolini, F., Bugatti, S., Frassi, M., Ruscitti, P., Morrone, M., La Torre, F., Cakir, I.Y., Akay, N., Kilic Konte, E., et al.. - In: FRONTIERS IN PHARMACOLOGY. - ISSN 1663-9812. - ELETTRONICO. - 17:(2026), pp. 1846937.0-1846937.0. [10.3389/fphar.2026.1846937]
Association between canakinumab dose and long-term remission in Still’s disease: insights from the AIDA network registry
Vitale, Antonio;Morrone, Maria;La Torre, Francesco;Cipriani, Paola;Maggio, Maria Cristina;Emmi, Giacomo;Parronchi, Paola;Conforti, Alessandro;
2026
Abstract
Objective – The primary aim of this study was to assess, in Still’s disease, whether the employment of canakinumab at a strictly on-label dose may increase the likelihood of treatment discontinuation due to study-defined long-term remission (LTR), compared with patients receiving lower doses. Methods – Patients were drawn from the international Autoinflammatory Disease Alliance (AIDA) Network registry dedicated to Still’s disease and stratified based on the starting canakinumab dose: the on-label group received either 300mg every 4 weeks or 150mg every 4 weeks (corresponding to 4mg/kg), while the underdosed group received 150mg every 4 weeks (corresponding to a dose not exceeding 3.5mg/kg). Bayesian regression models were implemented to estimate the probability of achieving long-term remission with subsequent canakinumab withdrawal in the two groups, as well as the mean differences in probabilities and posterior probabilities indicating whether the on-label group was superior in achieving the endpoint. Results – In total, 131 patients (16.7%) were enrolled, 81 (61.8%) receiving the on-label posology and 50 (38.2%) the underdosed posology. The estimated marginal posterior probability of canakinumab discontinuation due to LTR was 19% (CrI 7.5%–34.6%) in the on-label group and 3.9% (CrI 0.7%–15.2%) in the underdosed group, yielding a mean difference of 15.1% (CrI 1.4%–31.4%) and a posterior probability of 98.4%. This difference remained credible, with posterior probabilities ranging from 97.9% to 99.6%, irrespective of disease course or age at disease onset. Conclusion – On-label canakinumab dosing appears to increase the likelihood of study-defined LTR with subsequent treatment discontinuation, compared with underdosed treatment strategies.| File | Dimensione | Formato | |
|---|---|---|---|
|
fphar-17-1846937.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
2.69 MB
Formato
Adobe PDF
|
2.69 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



